Ose Immunotherapeutics, a French biotech company, claimed the efficacy of its Tedopi vaccination in boosting survival rates for certain lung cancer patients.

Tedopi revealed a 41% reduction in the risk of mortality compared to chemotherapy in a phase 3 clinical study comprising 219 patients from nine countries.

This hopeful discovery addresses a key need in the treatment of non-small cell lung cancer (NSCLC), a cancer form that is often less receptive to traditional medicines, and represents a substantial improvement in cancer therapy.

“A significant 41% reduction in the risk of death was observed, associated with an improved tolerance score and maintained quality of life,” said Professor Benjamin Besse from the Gustave Roussy Institute, the study’s lead author, in a statement.

Ose Immunotherapeutics’ vaccine was used in this trial as a third-line treatment, meaning that the patients had already received two other therapies.

“Further evaluation is clearly warranted in a second line of treatment of advanced and metastatic NSCLC, to potentially make this cancer vaccine available to hard-to-treat patients in failure and with high medical needs,” Besse added.

Ose Immunotherapeutics has confirmed that the Tedopi vaccine is effective in individuals carrying the HLA-A2 gene, which is found in about half of the population, and is administered every three weeks.

Nicolas Poirier, the company’s CEO said the recent results of the different trials “highlighted the promise of this new therapeutic class of vaccines”.

Tedopi is a therapeutic cancer vaccine that trains the immune system to recognize and destroy tumor cells, using the patient's own defense system to fight cancer.

The field of immunotherapy has made considerable advancements since the 2010s, and it has benefited from research during the pandemic, which "has accelerated the production of vaccines, specifically mRNA vaccines," according to Cancer Research UK.

The UK government has partnered with BioNTech to initiate cancer vaccine trials, aiming to treat 10,000 patients by 2030, and numerous immunotherapeutic treatments have been approved, with ongoing research ongoing.

Market Future Insight predicts the global cancer vaccines market to reach €22 billion by 2033, despite the high treatment costs. Notably, Ose Immunotherapeutics’ stock value surged by 60% on the Paris Stock Exchange following the trial result announcement.